stockrowEdgewise Therapeutics, Inc.
EWTX Healthcare Biotechnology
- EPS
- +2,846.5%
- Free cash flow
- −30.2%
Quarter to September 2026, against a year earlier
Follow EWTX
Alert me
Edgewise Therapeutics, Inc. (EWTX) Operating cash flow
Edgewise Therapeutics, Inc.'s operating cash flow for fiscal 2025 was −$143.8M, compared with −$109.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$201.9M. Over the past ten years it has ranged from −$143.8M (fiscal 2025) to −$14.6M (fiscal 2020) — the current reading is the lowest in ten years. Operating cash flow has fallen for 5 consecutive fiscal years. Edgewise Therapeutics, Inc. ranks 515th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$143.8M | — |
| FY2024 | −$109.0M | — |
| FY2023 | −$91.9M | — |
| FY2022 | −$52.6M | — |
| FY2021 | −$33.5M | — |
| FY2020 | −$14.6M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$78.3M | — |
| Jun 2026 | −$42.5M | — |
| Mar 2026 | −$42.5M | — |
| Dec 2025 | −$38.6M | — |
| 23 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. compare | $60.0M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$89.4M |
| ABCL AbCellera Biologics Inc. compare | −$94.9M |
| TNGX Tango Therapeutics, Inc. compare | −$143.9M |
| EWTX Edgewise Therapeutics, Inc. | −$158.4M |
| DFTX Definium Therapeutics, Inc. compare | −$168.0M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$190.0M |
| RLAY Relay Therapeutics, Inc. compare | −$212.2M |
| XENE Xenon Pharmaceuticals Inc. compare | −$337.5M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item